Trial Profile

A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jun 2024 According to a SAGE Therapeutics media release, additional work is ongoing to further analyze and understand the data including the relationship of changes in cognition to changes in function.
11 Jun 2024 Primary endpoint has been met. (Change From Baseline in the Huntingtons Disease Cognitive Assessment Battery (HD-CAB) Composite Score), according to a SAGE Therapeutics media release.
11 Jun 2024 Results presented in the SAGE Therapeutics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com